🇺🇸 FDA
Patent

US 9931311

Treating critically ill patients with intravenous ibuprofen

granted A61KA61K31/192A61K31/197

Quick answer

US patent 9931311 (Treating critically ill patients with intravenous ibuprofen) held by Cumberland Pharmaceuticals Inc. expires Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Cumberland Pharmaceuticals Inc.
Grant date
Tue Apr 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/192, A61K31/197, A61K45/06, A61K9/0019